Arbutus Financial Statements From 2010 to 2026
| ABUS Stock | USD 4.88 0.09 1.88% |
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
Check out the analysis of Arbutus Biopharma Correlation against competitors. Arbutus Biopharma Corp Company Current Valuation Analysis
Arbutus Biopharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arbutus Biopharma Current Valuation | 845.76 M |
Most of Arbutus Biopharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arbutus Biopharma Corp has a Current Valuation of 845.76 M. This is 94.11% lower than that of the Biotechnology sector and 81.79% lower than that of the Health Care industry. The current valuation for all United States stocks is 94.91% higher than that of the company.
Arbutus Biopharma Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arbutus Biopharma's current stock value. Our valuation model uses many indicators to compare Arbutus Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arbutus Biopharma competition to find correlations between indicators driving Arbutus Biopharma's intrinsic value. More Info.Arbutus Biopharma Corp is rated fifth in return on equity category among its peers. It is rated third in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Arbutus Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Arbutus Biopharma Financial Statements
Arbutus Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus infection, SARS-CoV-2, and other coronaviruses in the United States. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Arbutus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.